Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COLLABORATION REDUCES TIME IN FERMENTING COMPLEX BACTERIAL STRAINS, ENABLING CONTINUED FOCUS ON NEXT-GEN BIOLOGICAL CROP SOLUTIONS. BOSTON AND PLANO, TEXAS , DEC. 17, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS (NYSE: DNA, "GINKGO"), A PROVIDER OF RESEARCH AND DEVELOPMENT SERVICES AND TOOLS FOR BIOLOGICAL PRODUCT DEVELOPMENT AND AGRICEN, A LEADER IN THE DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BIOLOGICALAND SOIL AMENDMENTSOLUTIONS FOR PLANT NUTRITION AND HEALTH, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF THEIR INITIAL COLLABORATION TO DEVELOP AND OPTIMIZE A LOW-COST, EFFICIENT FERMENTATION PROCESS FOR COMPLEX BACTERIAL STRAINS USED AS A COMPONENT IN ONE OF AGRICEN'S SOIL AMENDMENT PRODUCTS.

GINKGO BIOWORKS AND AGRICEN ENTER COLLABORATION TO OPTIMIZE MANUFACTURING PROCESSES FOR A KEY AGRICULTURAL SOIL AMENDMENT

WALTHAM, MASS.--(BUSINESS WIRE)--THERMO FISHER SCIENTIFIC INC., THE WORLD LEADER IN SERVING SCIENCE, TODAY ANNOUNCED THE LAUNCH OF GIBCO BACTO CD SUPREME FPM PLUS AND GIBCO BACTO CD SUPREME FEED (2X), TWO NEXT-GENERATION CHEMICALLY-DEFINED FORMULATIONS THAT EXPAND THE GIBCO BACTO CD PORTFOLIO TO ENHANCE AND SIMPLIFY PLASMID DNA AND RECOMBINANT PROTEIN PRODUCTION USING ESCHERICHIA COLI (E. COLI). AS DEMAND FOR PLASMID DNA CONTINUES TO SURGE TO SUPPORT EXPANDING GENE THERAPY AND MRNA VACCIN.

THERMO FISHER SCIENTIFIC EXPANDS GIBCO BACTO PORTFOLIO WITH NEXT-GENERATION, CHEMICALLY DEFINED MEDIA TO BOOST E. COLI BIOMANUFACTURING PRODUCTIVITY

PROTEONIC LICENSES ITS 2G UNIC TECHNOLOGY TO GINKGO BIOWORKS FOR A BARDA-BACKED CONSORTIUM TO BOOST FAST, COSTEFFECTIVE MAB PRODUCTION AGAINST FILOVIRUSES

PROTEONIC 2G UNIC TECHNOLOGY LICENSED BY GINKGO BIOWORKS FOR BARDA-SUPPORTED CONSORTIUM ADVANCING MONOCLONAL ANTIBODY MANUFACTURING FOR ANTI-FILOVIRUS THERAPIES

BOSTON , DEC. 9, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA) TODAY ANNOUNCED ITS PARTNERSHIP WITH DEEP ORIGIN ON A 4.5-YEAR PROJECT FUNDED BY THE ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) COMPUTATIONAL ADME-TOX AND PHYSIOLOGY ANALYSIS FOR SAFER THERAPEUTICS( CATALYST ) PROGRAM. CATALYST IS LED BY ARPA-H HEALTH SCIENCE FUTURES MISSION OFFICE ACTING DEPUTY DIRECTOR ANDY KILIANSKI, PH.D.

GINKGO BIOWORKS PARTNERS ON DEEP ORIGIN-LED TEAM TO DEVELOP NEW TOOLS FOR PREDICTING DRUG SAFETY

THIS STRENGTHENS NEURALCLOUD'S EXPANSION INTO THE GLOBAL WELLNESS AND B2B HEALTH PRACTITIONER DELIVERY MODEL WITH HIGH-FIDELITY CARDIAC SIGNAL PROCESSING AND DIGITAL HEALTH INTEGRATION. PARTNERSHIP POSITIONS MAXYIELD AS A CORE AI ENGINE FOR NEXT-GENERATION SMART RINGS AND CONSUMER CARDIAC MONITORING INTO THE BROADER INTRINSICA PLATFORM.

AIML SUBSIDIARY NEURALCLOUD SOLUTIONS SIGNS COMMERCIAL TERM SHEET WITH CULMINATE H LABS TO DEPLOY MAXYIELD(TM) AND INSIGHT360(TM) INTO INTRINSICA'S DNA-GUIDED BIOFEEDBACK WELLNESS ECOSYSTEM

BOSTON , DEC. 5, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA) TODAY ANNOUNCED IT HAS BEEN AWARDED BY THE ENVIRONMENTAL MOLECULAR SCIENCES LABORATORY (EMSL) AT PACIFIC NORTHWEST NATIONAL LABORATORY (PNNL) A FOUR-YEAR, UP TO $47M CONTRACT TO CO-DESIGN, BUILD, AND INTEGRATE A HIGHTHROUGHPUT AUTOMATED PHENOTYPING PLATFORM (HTPAPP) IN SUPPORT OF THE MICROBIAL MOLECULAR PHENOTYPING CAPABILITY (M2PC). THE PLATFORM, SELECTED THROUGH A COMPETITIVE PROCUREMENT PROCESS, IS INTENDED TO ENABLE THE DEPARTMENT OF ENERGY'S (DOE) OFFICE OF SCIENCE, BIOLOGICAL AND ENVIRONMENTAL RESEARCH PROGRAM TO GENERATE RICH, REPRODUCIBLE MICROBIAL AND MICROBIOME DATA THAT ENSURE THE U.S. REMAINS AT THE FOREFRONT OF THE BIOECONOMY, SAFEGUARDING ECONOMIC, SOCIETAL, AND NATIONAL SECURITY BENEFITS WHILE MAINTAINING GLOBAL LEADERSHIP IN BIOTECHNOLOGY INNOVATION.

GINKGO BIOWORKS SELECTED BY PNNL TO DELIVER A MODULAR, HIGHTHROUGHPUT PHENOTYPING PLATFORM FOR DOE'S M2PC

CAMBRIDGE, MASS. , DEC. 3, 2025 /PRNEWSWIRE/ -- STRM.BIO, A START-UP BIOTECHNOLOGY COMPANY PIONEERING NON-VIRAL DELIVERY TECHNOLOGIES FOR IN VIVO CELL AND GENE THERAPY, TODAY ANNOUNCED THAT IT HAS BEEN AWARDED A CONTRACT FROM THE ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) THROUGH ITS ENGINEERING OF IMMUNE CELLS INSIDE THE BODY (EMBODY) PROGRAM.

STRM.BIO AWARDED ARPA-H CONTRACT TO ADVANCE MEGAKARYOCYTE-DERIVED VESICLE PLATFORM FOR IN VIVO CELL ENGINEERING AND GENE THERAPY

BOSTON , NOV. 18, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA) TODAY ANNOUNCED ITS PARTNERSHIP WITH THE INSTITUTE FOR GENOMIC BIOLOGY AT THE UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN ON A FIVE-YEAR INITIATIVE FUNDED BY THE ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H). THE COLLABORATION, MICROBE/PHAGE INVESTIGATION FOR GENERALIZED HEALTH THERAPY (MIGHTY), AIMS TO DEVELOP INNOVATIVE NEW TREATMENTS FOR ORAL HEALTH BY LEVERAGING GINKGO'S ADVANCED CAPABILITIES IN WORKING WITH COMPLEX MICROBIAL CONSORTIA.

GINKGO BIOWORKS PARTNERS ON ILLINOIS-LED TEAM TO DEVELOP INNOVATIVE NEW TREATMENTS FOR ORAL HEALTH

GINKGO PROVIDES AN UPDATE ON ITS THIRD QUARTER FINANCIAL RESULTS BOSTON , NOV. 6, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO") TODAY ANNOUNCED ITS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. THE UPDATE, INCLUDING A WEBCAST SLIDE PRESENTATION WITH ADDITIONAL DETAILS ON THE THIRD QUARTER, AS WELL AS SUPPLEMENTAL FINANCIAL INFORMATION WILL BE AVAILABLE AT INVESTORS.GINKGOBIOWORKS.COM.

GINKGO BIOWORKS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

DEMONSTRATED FEASIBILITY OF EFFECTIVE DNA DELIVERY WITH COMPANY'S XPHORE NANOPARTICLE TECHNOLOGY DNA DELIVERY TECHNOLOGY TO BE OFFERED AS GENEPHORE TO BIOTECH / PHARMA COMPANIES ADDRESSING LARGE AND GROWING MARKET HAMILTON, BERMUDA / ACCESS NEWSWIRE / NOVEMBER 3, 2025 / ALTAMIRA THERAPEUTICS LTD. ("ALTAMIRA" OR THE "COMPANY") (OTCQB:CYTOF), A COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING NUCLEIC ACID DELIVERY TECHNOLOGY FOR TARGETS BEYOND THE LIVER, TODAY ANNOUNCED THAT ITS NANOPARTICLE-BASED DELIVERY PLATFORM WAS SUCCESSFULLY TESTED TO DELIVER DNA MOLECULES.

ALTAMIRA THERAPEUTICS ANNOUNCES SUCCESSFUL NANOPARTICLE-BASED DELIVERY OF DNA MOLECULES

GINKGO AND PARTNERS TO DEVELOP MONOCLONAL ANTIBODY BIOMANUFACTURING INNOVATIONS AND TO PRODUCE AN ANTI-FILOVIRUS MEDICAL COUNTERMEASURE BOSTON , NOV. 3, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS (NYSE: DNA) ANNOUNCED TODAY THAT IT HAS BEEN AWARDED A CONTRACT THROUGH THE BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY'S (BARDA) BIOPHARMACEUTICAL MANUFACTURING PREPAREDNESS CONSORTIUM (BIOMAP-CONSORTIUM) TO DEVELOP INNOVATIONS THAT STRENGTHEN AND REDUCE THE COSTS OF DOMESTIC BIOMANUFACTURING OF MONOCLONAL ANTIBODIES (MABS) TO PROTECT AGAINST AND TREAT INFECTION BY FILOVIRUSES SUCH AS EBOLA (EBOV) AND SUDAN VIRUSES (SUDV). THE PROJECT HAS A TOTAL CONTRACT VALUE OF UP TO $22.2 MILLION AND SEEKS TO DEPLOY THESE INNOVATIONS TO PRODUCE THE ANTI-FILOVIRUS MABS COCKTAIL OF 1C3 AND 1C11, DISCOVERED AND DEVELOPED BY EMORY UNIVERSITY.

GINKGO BIOWORKS AWARDED PROJECT AGREEMENT THROUGH BARDA'S BIOMAP-CONSORTIUM

BOSTON , OCT. 31, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS (NYSE: DNA) TODAY ANNOUNCED THAT THE COMPANY HAS EXTENDED ITS MULTI-YEAR STRATEGIC PARTNERSHIP WITH BAYER TO ADVANCE RESEARCH AND DEVELOPMENT OF BIOLOGICAL PRODUCTS FOR AGRICULTURE. WITH THE EXTENSION OF THIS PARTNERSHIP, WHICH BEGAN IN 2017, BOTH PARTIES WILL BUILD ON THE SUCCESS OF THEIR ONGOING COLLABORATION TO DEVELOP INNOVATIVE MICROBIAL NITROGEN FIXATION.

GINKGO BIOWORKS AND BAYER EXTEND MULTI-YEAR STRATEGIC PARTNERSHIP TO ACCELERATE NEXT GENERATION BIOLOGICAL SOLUTIONS FOR AGRICULTURE

PRESENTATION AND Q&A SESSION SCHEDULED FOR POST-MARKET ON THURSDAY, NOVEMBER 6, 2025 BOSTON , OCT. 30, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO") TODAY ANNOUNCED THAT IT PLANS TO HOST A PRESENTATION AND Q&A SESSION REVIEWING BUSINESS PERFORMANCE FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, ON THURSDAY, NOVEMBER 6, 2025,BEGINNING AT 4:30 P.M. ET. THE PRESENTATION DETAILS AND WEBCAST LINK WILL BE AVAILABLE ON GINKGO'S INVESTOR RELATIONS WEBSITE AT HTTPS://INVESTORS.GINKGOBIOWORKS.COM , AND A REPLAY WILL BE MADE AVAILABLE.

GINKGO BIOWORKS ANNOUNCES DATE OF THIRD QUARTER 2025 RESULTS PRESENTATION

MILAN, OCT. 24, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER COMPANY IN IMMUNO-ONCOLOGY, AND ANEMOCYTE, A LEADING PROVIDER OF ADVANCED THERAPY AND NUCLEIC ACIDS SOLUTIONS, TODAY ANNOUNCED A STRATEGIC COLLABORATION WITH A FOCUS ON OFF-THE-SHELF LENTIVIRAL VECTOR (LVV) PLASMID DNA TECHNOLOGY PLATFORM. THIS NEW AGREEMENT BUILDS AND EXPANDS ON THE EXISTING SUCCESSFUL PARTNERSHIP BETWEEN THE TWO COMPANIES, WHICH HAS FOCUSED ON THE PRODUCTION OF PLASMID DNA.

GENENTA AND ANEMOCYTE ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE OFF-THE-SHELF LVV PLASMID DNA PRODUCTION

GINKGO BIOWORKS TO APPLY ITS RNA CONSTRUCT DESIGN EXPERTISE TO DEVELOP LONG-LIVED, TISSUE-SPECIFIC, AND HIGHLY POTENT IN VIVO CAR THERAPIES FOR AUTOIMMUNE DISEASES BOSTON , OCT. 23, 2025 /PRNEWSWIRE/ -- GINKGO BIOWORKS (NYSE: DNA) TODAY ANNOUNCED A COLLABORATION WITH STRM.BIO AND THE UNIVERSITY OF BRITISH COLUMBIA (UBC) AS PART OF THE ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH'S (ARPA-H) ENGINEERING OF IMMUNE CELL INSIDE THE BODY ( EMBODY ) PROGRAM. EMBODY IS LED BY ARPA-H PROGRAM MANAGER DARIAFEDYUKINA, PH.D.

GINKGO BIOWORKS IN PARTNERSHIP WITH STRM.BIO AND UNIVERSITY OF BRITISH COLUMBIA IN PROJECT TO DEVELOP IN VIVO CAR THERAPIES UNDER ARPA-H'S EMBODY PROGRAM

PUBLICATION INCLUDES COMPLETE DATA FOR ALL PARTICIPANTS (N=39) UP TO WEEK 72, FURTHER DEMONSTRATING DURABLE AND TOLERABLE EXPRESSION OF DMABS EFFECTIVE TARGET BINDING AND CONFIRMED FUNCTIONAL ACTIVITY THROUGH WEEK 72 NO IMMUNE REJECTION OF THEDMABS DETECTED ACROSS ~1,000 BLOOD SAMPLES MOST COMMON SIDE EFFECTS WERE MILD, TEMPORARY INJECTION SITE REACTIONS SUCH AS PAIN AND REDNESS; NO SERIOUS ADVERSE EVENTS (SAES) RELATED TO STUDY DRUG PLYMOUTH MEETING, PA. , OCT. 21, 2025 /PRNEWSWIRE/ -- INOVIO (NASDAQ: INO), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING DNA MEDICINES TO HELP TREAT AND PROTECT PEOPLE FROM HPV-RELATED DISEASES, CANCER, AND INFECTIOUS DISEASES, TODAY ANNOUNCED RESULTS FROM A PHASE 1 PROOF-OF-CONCEPT TRIAL EVALUATING DMABS FOR COVID-19 WERE PUBLISHED ONLINE IN NATURE MEDICINE UNDER THE TITLE"SAFETY AND PHARMACOKINETICS OF SARS-COV-2 DNA-ENCODED MONOCLONAL ANTIBODIES IN HEALTHY ADULTS: A PHASE 1 TRIAL.

Ginkgo Bioworks Holdings, Inc.

DNA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ginkgo Bioworks Holdings, Inc.

DNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DNA